Obeticholic Acid
- CAS No.
- 459789-99-2
- Chemical Name:
- Obeticholic Acid
- Synonyms
- 6-Ethylchenodeoxycholic acid;Ocaliva;(R)-4-((3R,5S,6R,7R,8S,9S,10S,13R,14S,17R)-6-ethyl-3,7-dihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoic acid;9470;1osv;6alph;C15636;6-Ecdca;CS-1441;pha,7aL
- CBNumber:
- CB92484652
- Molecular Formula:
- C26H44O4
- Molecular Weight:
- 420.63
- MOL File:
- 459789-99-2.mol
- MSDS File:
- SDS
- Modify Date:
- 2024/9/4 23:37:13
| Melting point | 108-110 °C |
|---|---|
| Boiling point | 562.9±25.0 °C(Predicted) |
| Density | 1.091 |
| storage temp. | -20°C |
| solubility | Soluble in DMSO (up to 35 mg/ml) or in Ethanol (up to 25 mg/ml) |
| form | White solid. |
| pka | 4.76±0.10(Predicted) |
| color | White |
| Stability | Stable for 2 years from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 2 months. |
SAFETY
Risk and Safety Statements
| Symbol(GHS) |  GHS07 |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Signal word | Warning | |||||||||
| Hazard statements | H315-H319-H335 | |||||||||
| Precautionary statements | P261-P305+P351+P338 | |||||||||
| HS Code | 2918199890 | |||||||||
| NFPA 704 |
|
Obeticholic Acid price More Price(3)
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Sigma-Aldrich(India) | SML3096 | Obeticholic acid ≥98% (HPLC) | 459789-99-2 | 5MG | ₹8356.9 | 2022-06-14 | Buy |
| Sigma-Aldrich(India) | SML3096 | Obeticholic acid ≥98% (HPLC) | 459789-99-2 | 25MG | ₹33730.7 | 2022-06-14 | Buy |
| Sigma-Aldrich(India) | CDS024140 | 6-Ethylchenodeoxycholic acid | 459789-99-2 | 25MG | ₹33958.03 | 2022-06-14 | Buy |
Obeticholic Acid Chemical Properties,Uses,Production
Description
Obeticholic acid is a potent and selective farnesoid X receptor agonist that promotes the flow of bile in the liver. The drug was approved by the USFDA for the treatment of the rare chronic liver disease primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with inadequate response to UDCA or as a single agent therapy in adults unable to tolerate UDCA. Obeticholic acid was discovered at the Università de Perugia and developed by Intercept Pharmaceuticals. Obeticholic acid has also been granted orphan drug designation for the treatment of primary sclerosing cholangitis and primary biliary cirrhosis and has received breakthrough therapy designation for the treatment of patients with nonalcohol steatohepatitis (NASH) with liver fibrosis.
Uses
6-Ethylchenodeoxycholic Acid is a derivative of the bile acid Chenodeoxycholic Acid (C291900). 6-Ethylchenodeoxycholic Acid is a potent activator of the farnesoid X nuclear receptor which reduces liver fat and fibrosis in animal models of fatty liver disease.
Definition
ChEBI: A dihydroxy-5beta-cholanic acid that is chenodeoxycholic acid carrying an additional ethyl substituent at the 6alpha-position. A semi-synthetic bile acid which acts as a farnesoid X receptor agonist and is used for treatme t of primary biliary cholangitis.
Enzyme inhibitor
This semisynthetic bile acid analogue (FW = 420.63 g/mol; CAS 459789- 99-2), also named INT-747, 6α-ethyl-chenodeoxycholate, and (3α,5β,6α, 7α)-6-ethyl-3,7-dihydroxycholan-24-oic acid, is an analogue of the naturally occurring bile acid (FW = 392.57 g/mol; CAS 474-25-9). The latter is synthesized in the liver, where it conjugated to form taurochenodeoxycholate and glycol-chenodeoxycholate, reducing its pKa and increasing retention in the gastrointestinal tract, until reabsorption by the ileum. Chenodeoxycholate is the most active physiological ligand known for the farnesoid X receptor, or FXR (encoded by the NR1H4 gene in humans) that translocates to the nucleus, dimerizes, and binds to hormone response elements. Obeticholic acid reduces bacterial translocation and invasion in cirrhotic rats by restoring intestinal barrier integrity (through increased expression of tight junction proteins) and by inhibiting inflammation. Obeticholate likewise up-regulated expression of the FXR-associated gene small heterodimer partner (SHP).
Obeticholic Acid Preparation Products And Raw materials
Raw materials
Preparation Products
| Supplier | Tel | Country | ProdList | Advantage | Inquiry |
|---|---|---|---|---|---|
| Siddhivinayakchemicals | +91-912225190111 +91-9819773074 | Mumbai, India | 42 | 58 | Inquiry |
| Viruj Pharmaceuticals Pvt Ltd | +91-9441591589 +91-9441591589 | Hyderabad, India | 33 | 58 | Inquiry |
| Mankind Pharma Limited | +91-1146541111 +91-1146541111 | New Delhi, India | 23 | 58 | Inquiry |
| Hetero Drugs Limited | +91-4023704923 +91-4023704923 | Telangana, India | 296 | 58 | Inquiry |
| Solara Active Pharma Sciences Ltd | +91-8046632100 +91-7075706520 | Bangalore, India | 65 | 58 | Inquiry |
| Medchem Labs | +91-7288889564 +91-7288889555 | Telangana, India | 25 | 58 | Inquiry |
| Sekhment pharmaventures | +91-9030088669 +91-9030088669 | Mumbai, India | 105 | 58 | Inquiry |
| Alembic Pharmaceuticals Limited | +91-2652280880 +91-2652280550 | Gujarat, India | 115 | 58 | Inquiry |
| Optimus Pharma Pvt Ltd (Sekhmet Pharmaventures)) | +91-9100091731 +91-9573334999 | Telangana, India | 57 | 58 | Inquiry |
| Biophore India Pharmaceuticals Pvt Ltd | +91-9100031592 +91-9030907714 | Telangana, India | 134 | 58 | Inquiry |
Related articles
- About Obeticholic Acid
- Obeticholic Acid is used alone or in combination treatment for a certain liver disease (primary biliary cholangitis-PBC). This....
- Aug 16，2019
459789-99-2(Obeticholic Acid)Related Search:
1of4
chevron_right